VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
Jaime Feliú-BatlleRocio Garcia-CarboneroJaume CapdevilaInmaculada GuaschVicente Alonso-OrdunaCarlos LopezPilar Garcia-AlfonsoCarmen CastanonIsabel SevillaLaura CerezoCarles ConillBegona Quintana-AngelMaria E SanchezIsmael GhanemMarta Martin-RichardMiriam Lopez-GomezAna LeonMonica CaroTeresa FernandezJoan MaurelPublished in: Cancer medicine (2019)
Panitumumab addition to MMC-5FU regimen in SCCAC patients increases toxicity and does not improve patients' outcomes. RT plus MMC-5FU remains the standard of care for localized SCCAC patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- randomized controlled trial
- radiation therapy
- clinical trial
- early stage
- squamous cell carcinoma
- palliative care
- type diabetes
- adipose tissue
- high grade
- oxidative stress
- squamous cell
- patient reported outcomes
- skeletal muscle
- patient reported
- radiation induced
- pain management
- combination therapy
- rectal cancer
- glycemic control